Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015 Sep;26(9):1877-83 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/26141208.
Compare quality appraisals for each clinical question
- What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
- What is the optimal systemic therapy regimen in selected patients for treatment of stage IV inoperable NSCLC?
- What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?